Global Cataract Surgery Devices And Equipment Market

Ophthalmology is a branch of science that deals with the structure, function of eyes. Ophthalmic devices are used in the diagnosis and treatment of eye related diseases. The main types of ophthalmic devices are vision care devices and equipment, cataract surgery devices and equipment, refractive surgery devices and equipment, and diagnostic and monitoring ophthalmic devices and equipment. Cataract surgery devices and equipment are devices that emit ultrasound waves that soften and break up the lens so that it can be removed by suction. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end uses involved are hospitals and clinics, diagnostic laboratories, and others. The ophthalmic devices market research report is one of a series of new reports from The Business Research Company that provides ophthalmic devices market statistics, including ophthalmic devices industry global market size, regional shares, competitors with a ophthalmic devices market share, detailed ophthalmic devices market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmic devices industry. This ophthalmic devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ophthalmic devices market grew from $36.36 billion in 2022 to $39.24 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The ophthalmic devices market is expected to grow to $51.12 billion in 2027 at a CAGR of 6.8%. The femtosecond laser is increasingly being used in cataract surgeries as it provides greater precision than traditional surgical methods. A femtosecond laser emits optical pulses with a duration of below 1 ps (ultrashort pulses), i.e., in the domain of femtoseconds (1 fs = 10-15 s). The medical procedure using this laser is done under computer-guided OCT imaging, hence there is higher control and reliability of the incisions concerning size, shape, and location than conventional procedures. This process also reduces the risk associated with a human error during the surgery and has a shorter recovery period. Major companies manufacturing femtosecond laser ophthalmic equipment are Myalcon and Precision Lens. Robotic-assisted eye surgeries are being widely used by healthcare service organizations to improve treatment outcomes. Robot-assisted surgeries allow surgeons to perform complex eye operations with improved precision, amplified scale of motion, reduced tremor, task automation, and flexibility. For instance, the mechatronics and control laboratory and the Jules stein eye institute together developed an intraocular robotic interventional and surgical system (IRISS) which is capable of performing both anterior and posterior intraocular surgery. This system consists of master surgical manipulators to manipulate two surgical instruments simultaneously through tiny ocular incisions and microscope-mounted cameras for 3-D teleoperated surgical visualization. Preceyes BV also developed PRECEYES Surgical System to perform robot-assisted operations inside the eye. Major companies in the ophthalmic devices market include Luxottica Group S.p.A., Johnson & Johnson, Hoya Corporation, CooperVision AG, Bausch Health, Companies Inc., Carl Zeiss AG, Flex Ltd., Nidek Co. Ltd., Topcon Corporation, and Rostec State Corporation. North America was the largest region in the global ophthalmic devices market in 2022. Asia-Pacific was the second largest region in the global ophthalmic devices market. Africa. was the smallest region in the global ophthalmic devices market. The regions covered in the ophthalmic devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the ophthalmic devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The ophthalmic devices consist of sales of instruments such as optical coherence tomography scanners, perimeters/visual field analyzers, ophthalmic pachymeters, wavefront aberrometers, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ophthalmic devices market is segmented - 1) By Type: Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Ophthalmic medical lasers are used in the treatment of diseases related to the eye. The main products of the ophthalmic medical lasers are diode lasers, femtosecond lasers, excimer lasers for aromatherapy, ND:YAG lasers, and others. A diode laser is a semiconductor that produces coherent radiation with the same frequency and phase, either in the visible or infrared spectrum, using a p-n junction.The various applications include refractive error correction, cataract removal, diabetic retinopathy, glaucoma, age-related macular degeneration, and others. The various end-users are hospitals, specialty clinics, and ambulatory surgery centres. The ophthalmic medical lasers market research report is one of a series of new reports from The Business Research Company that provides ophthalmic medical lasers market statistics, including ophthalmic medical lasers industry global market size, regional shares, competitors with a ophthalmic medical lasers market share, detailed ophthalmic medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmic medical lasers industry. This ophthalmic medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ophthalmic medical lasers market grew from $1.12 billion in 2022 to $1.2 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The ophthalmic medical lasers market is expected to grow from $1.55 billion in 2027 at a CAGR of 6.5%. The rising incidence of ocular disorders is driving the demand for the ophthalmic medical lasers market. Ocular disorders are the ones that affect vision and eye health in patients of all ages and treatment with lasers helps reshape the eye cornea for better focus, which contributes to an improved vision. According to a study by the lancet, in 2020, 43.3 million people were blind. 295 million people had moderate to severe vision impairment, 258 million had mild vision impairment. The rise in the incidence of ocular disease that requires laser treatment contributes to the growth of the ophthalmic medical lasers market. The availability of alternative therapies for vision correction is expected to hinder the ophthalmic medical lasers market. The alternatives for lasers in ophthalmology include using a lens for correcting the vision using techniques such as Phakic Intraocular Lens Implants, and Refractive Lens Exchange Surgery. According to the statistics by the American Society of Cataract and Refractive Surgery (ASCRS), 95% of patients who choose to have a standard IOL procedure, which is considered safe for cataract surgery, experience fully restored vision. Therefore, the availability of alternative therapies to correct vision is expected to hamper the ophthalmic medical lasers market. Companies are investing in manufacturing devices that incorporate next-generation technology to treat ocular diseases. Following the trend, In Feb 2020, IRIDEX Corporation, an innovative ophthalmic laser-based medical products provider for the treatment of glaucoma and retinal diseases has launched the second generation of the MicroPulse P3® Device that gives greater stability, visualization, coupling, and fit. In June 2020, Lumibird, a leading France-based laser technology specialist acquired all of Ellex's laser and ultrasound activities for $70 million. Through this acquisition, the Lumibird group aimed to strengthen its current product portfolio with complementary high-quality products, and extend its geographical presence, particularly in the US and Japan, as the acquisition included Ellex’s R&D and production site in Adelaide and the commercial subsidiaries based in Australia, Japan, the US, France, and Germany. Ellex is a leading Australia-based ophthalmic equipment manufacturer. Major players in the ophthalmic medical lasers market are Alcon Laboratories Inc., Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Incorporated, Topcon Corporation, Ziemer Ophthalmic Systems AG, IRIDEX Corporation, and NIDEK Co. Ltd., Lumenis Ltd., and Johnson & Johnson. North America was the largest region in the ophthalmic medical lasers market in 2022. Asia-Pacific was the second largest region in the global ophthalmic medical lasers market report. The regions covered in the global ophthalmic medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the ophthalmic medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The ophthalmic medical lasers market consists of sales of instruments such as SLT lasers, excimer lasers, cyclodiode lasers, and femtosecond lasers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global ophthalmic medical lasers market is segmented - 1) By Product: Diode Lasers, Femtosecond Lasers, Excimer Lasers Aromatherapy, ND:Yag Lasers, Other Products 2) By End User: Hospitals, Specialty Clinics and Ambulatory Surgery Centres 3) By Application: Refractive Error Correction, Cataract Removal, Diabetic Retinopathy, Glaucoma, Age-Related Macular Degeneration, Other Applications

Diagnostic and monitoring ophthalmic devices and equipment are used for the diagnosis and monitoring of diseases related to the retina and cornea by measuring affix lenses and refractive errors. These devices also help identify the intraocular lenses (IOLs) and analyze the visual field. The main product types in the diagnostic and monitoring ophthalmic devices and equipment are optical coherence tomographers, ophthalmic ultrasound imaging systems, fundus cameras, ophthalmoscopes, keratometers, specular microscopes., tonometers, slit lamps, retinoscopes, and others (dioptometers, optotype projector, perimeters, and biometers, pachymeters, autorefractors/phoropters, corneal topographers, wavefront aberrometer, wavefront aberrometer). Fundus cameras are used for diagnosing and monitoring and are used in imaging of a rear eye. These are used in various applications such as retinal evaluation, glaucoma detection, and monitoring, surgical evaluation, general examination, intraoperative devices, and refraction equipment. The diagnostic and monitoring ophthalmic devices are used in hospitals, clinics, diagnostic laboratories, and research centres. The diagnostic and monitoring ophthalmic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides diagnostic and monitoring ophthalmic devices and equipment market statistics, including diagnostic and monitoring ophthalmic devices and equipment industry global market size, regional shares, competitors with a diagnostic and monitoring ophthalmic devices and equipment market share, detailed diagnostic and monitoring ophthalmic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic and monitoring ophthalmic devices and equipment industry. This diagnostic and monitoring ophthalmic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global diagnostic and monitoring ophthalmic devices and equipment market size will grow from $2.5 billion in 2022 to $2.72 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diagnostic and monitoring ophthalmic devices and equipment market size is expected to grow from $3.6 billion in 2027 at a CAGR of 7.3%. The increasing prevalence of eye diseases is expected to drive the demand for diagnostic and monitoring equipment in the ophthalmic devices industry. The rise in surgeries associated with eye disorders like cataracts, diabetic retinopathy, and glaucoma has increased the demand for diagnostic and monitoring ophthalmic devices. According to a study, 4 out of 10 people have been found to have cataract disease in their early stages of life. The absolute number of cataract blind in 2020 would be 8.25 million, due to a substantial increase in the population above 50 years in India. Lack of awareness about eye diseases mostly in developing and underdeveloped nations is expected to hinder the growth of the diagnostic and monitoring ophthalmic devices and equipment market. BLack of awareness of eye disorders results in fewer patients going for a routine eye check-up or diagnosis of the disorder, impacting the demand for diagnostic and monitoring ophthalmic equipment. According to a study conducted by the vision impact institute, 42% of drivers in India have vision-related problems leading to 59% of road accidents. According to WHO, 550 million people in the country need vision correction and to achieve this, companies should increase awareness & provide vision care to people living in rural and semi-urban areas. Advanced eye care medical devices equipped with artificial intelligence (AI) and machine learning (ML) are the new trends in the ophthalmic diagnostic and monitoring equipment market. AI and ML-equipped medical devices can not only quickly interpret the eyes of the patient with better accuracy but also recommend a suitable treatment for the patient. Deepmind, a subsidiary of Alphabet Inc. has developed an AI-based system that is capable of analyzing 3D retinal OCT scans for detecting severe diseases like glaucoma, retinopathy, macular degeneration, and 50 different types of eye diseases at their early stage. The increased regulatory compliance norms by the Food and Drug Administration (FDA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have impacted the market making the approval/regulation process for diagnostic and monitoring ophthalmic devices strenuous. Complex and tedious premarket and postmarket submissions by FDA may increase the product release time and incur heavy costs on device development. The MHRA considers a medical device to be any equipment used for the diagnosis or treatment of disease, or for monitoring patients and recommends Yellow card reporting for ophthalmic devices and products as well. All the adverse events and the causes for any untoward incidents must be reported in the yellow card, allowing the equipment to be monitored thoroughly for enhanced patient safety. In July 2020, Topcon, a company manufacturing optical equipment based in Japan acquired Elektron Eye Technology for an undisclosed amount. This acquisition includes the products of the Henson line of perimetry such as Henson 9000 and 7000 that perform suprathreshold glaucoma screening and the product manufacturing will remain in the UK. Elektron Eye Technology is a company operating in the diagnostic and monitoring of ophthalmic devices based in the UK. Major players in the diagnostic and monitoring ophthalmic devices and equipment market are Carl Zeiss Meditec, Alcon, Bausch + Lomb, Haag-Streit, Topcon Corporation, Nidek Co. Ltd., Abbott Medical Optics, Johnson and Johnson Vision Care, Essilor International S.A, and Ziemer Ophthalmic Systems AG. North America was the largest region in the global diagnostic and monitoring ophthalmic devices and equipment market in 2022. Asia-Pacific was the second largest market in diagnostic and monitoring ophthalmic devices and equipment market. The regions covered in the global diagnostic and monitoring ophthalmic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the diagnostic and monitoring ophthalmic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The Diagnostic and monitoring ophthalmic devices and equipment market consist of sales of ultrasound imaging systems ophthalmoscopes, corneal topographers, specular microscopes, slit lamps, fundus cameras, anomaloscope, haploscope, ophthalmic lens gauge, stereopsis measuring Instrument, retinoscopes, stereoscope, and others that are used for diagnosis and monitoring of ophthalmic diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global diagnostic and monitoring ophthalmic devices and equipment market is segmented - 1) By Product Type: Optical coherence tomographers, Ophthalmic ultrasound imaging systems, Fundus cameras, Ophthalmoscopes, Keratometers, Specular microscopes., Tonometers, Slit Lamps, Retinoscopes, Others(Dioptometers, Optotype projector, Perimeters, and Biometers,Pachymeters,Autorefractors/phoropters,Corneal topographers,Wavefront abberometers,Wavefront abberometers) 2) By End User: Hospitals, Clinics, Diagnostic Laboratories, Research Centers 3) By Application: Retinal evaluation, Glaucoma detection and monitoring, Surgical evaluation, General examine, Intraoperative devices, Refraction equipment

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices

Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the back of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD). The macular degeneration treatment is used to treat macular degeneration eye disease and slow the disease and prevent severe loss of vision. The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. In early-stage AMD, the macula changes, with medium-sized drusen deposits and no pigment changes, but this does not impact vision. Intermediate AMD is when vision may get blurry or wavy with large drusen or pigment changes. In late-stage AMD, the central vision fails completely, causing vision loss. The different types of macular degeneration treatments include wet macular degeneration and dry macular degeneration. The different routes of administration of macular degeneration treatment include oral, injectable, and others used by different end-users such as ambulatory surgical centers, ophthalmic clinics, and hospitals. The macular degeneration treatment research report is one of a series of new reports from The Business Research Company that provides macular degeneration treatment statistics, including macular degeneration treatment industry global market size, regional shares, competitors with macular degeneration treatment shares, detailed macular degeneration treatment segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global macular degeneration treatment market size grew from $8.44 billion in 2022 to $9.43 billion in 2023 at a compound annual growth rate (CAGR) of 11.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The macular degeneration treatment market size is expected to grow to $14.3 billion in 2027 at a CAGR of 11.0%. The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision. According to a study done in Tanzania in 2020 about the prevalence of retinal diseases and associated risk factors, out of 1,007 people, the prevalence of vitreoretinal disorders was 22.8% (230/1,007). The study was conducted by OSLI Retina, which focuses solely on retinal diseases, surgery, and pharmacotherapy. The leading retinal diseases were age-related hypertensive macular scars (2.7%), retinopathy (4.5%), and degeneration (7.0%). According to the American Academy of Opthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market. The development of advanced therapies is a key trend gaining popularity in the macular degeneration treatment market. Advanced therapy, including gene therapy, for the treatment of disease has seen development in recent years, particularly in the world of inherited retinal disease. For instance, in October 2021, Genentech, a US-based biotechnology company, announced that FDA has approved Susvimo, a new treatment for wet age-related macular degeneration. Susvimo is the first wet AMD treatment to offer an alternative to the standard-of-care eye injections required as frequently as once per month in the last 15 years. Susvimo will help people with wet AMD retain their vision with as few as two treatments per year by continually injecting medication into the eye via a refillable implant. In September 2021, Novartis, a Swiss-based pharmaceutical company, acquired Arctos Medical for an undisclosed amount. The acquisition is expected to allow Novartis to find treatments for patients with vision loss and leverage the potential of optogenetics as the basis of successful therapeutics. Arctos Medical is a Switzerland-based developer of smart medical devices and gene therapy approaches for ophthalmological diseases for treating blindness. Major players in the macular degeneration treatment market are Novartis AG, Bausch Health Companies Inc., Regenxbio Inc., F Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., GlaxoSmithKline plc, Bayer AG, Neurotech Pharmaceuticals Inc., Ophthotech Corporation, StemCells Inc., Pfizer Inc., Santen Pharmaceuticals, Alimera Sciences Inc., Aerie Pharmaceutical Inc., Panoptica, Allergan Inc., Valeant Pharmaceuticals, and Rxi Pharmaceuticals Inc. In 2022, North America will be the largest region in the macular degeneration treatment market. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the Macular Degeneration Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global macular degeneration treatment market is segmented - 1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD 2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals 3) By Route of Administration: Oral, Injectable, Other Route of Administration 4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Vision care devices and equipment are used to treat eye vision problems. The main types of vision care devices and equipment are intraocular lenses, ophthalmic lasers, glaucoma drainage devices, and others. The main types of vision care devices and equipment are intraocular lenses, ophthalmic lasers, glaucoma drainage devices, contact lenses, and others. An intraocular lens is an artificial replacement for the lens of the eye. The various application of vision care devices and equipment are vision care, diagnosis, and surgery that are used by various end-users such as hospitals, ambulatory surgery centres, optical centres, and others. The vision care devices and equipment market research report is one of a series of new reports from The Business Research Company that provides vision care devices and equipment market statistics, including vision care devices and equipment industry global market size, regional shares, competitors with a vision care devices and equipment market share, detailed vision care devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the vision care devices and equipment industry. This vision care devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global vision care devices and equipment market size will grow from $27.1 billion in 2022 to $29.24 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The vision care devices and equipment market size is expected to grow to $38.1 billion in 2027 at a CAGR of 6.8%. The rising use of electronic devices is a continuous driver for the growth of the vision care devices and equipment market. Usage of laptops, mobiles, PCs, and other electronic devices has increased in day-to-day life, which is the major factor responsible for eye-related problems. According to a survey by Deloitte, Americans collectively check their phones over 8 billion times per day. On average, every person spends about five hours daily browsing the internet and using apps. Lack of awareness among people regarding eye diseases including glaucoma, macular degeneration, and others affects the market growth of the vision care devices and equipment market. According to a study in the USA, around one-third of survey respondents are not aware of glaucoma, more than half were unaware of macular degeneration, and one-fourth of survey respondents were not aware of any eye conditions. Technological advancement in vision care devices has transformed eye care. Vision technology has witnessed some great scientific breakthroughs and innovations in the past few years and these advances are rapidly changing the future of those with chronic eye conditions. The innovation includes DriveSafe lenses with anti-glare coating to help with poor driving conditions, photochromic contact lenses that block the sun's harmful UV rays, and blue light blocking glasses among others. Major companies such as Johnson & Johnson Vision have invested in adaptive lenses. In the USA, eyeglass frames and prescription lenses are regulated by FDA. These are classified as class 1 medical devices. These devices are exempt from filing a premarket notification application, and FDA clearance before marketing a Class 1 device in the United States. Due to this prescription eyeglasses sold via the internet are still considered an FDA-regulated product. In European Union (EU) medical devices including contact lenses are regulated by European Commission (EC). The EC works in close conjunction with each country ('Member State) respected Health Authorities to integrate the various national requirements into a single law that could be rolled out and applied across the EU. The EU region is set to roll out new medical device regulations (MDR) in 2020, under which the contact lenses are included. These new regulations shed light on the importance of prioritizing safety and efficacy before achieving marketing approval, and on transparency of device information. These new EU regulations will have an impact on contact lens approvals in Europe. Major players in the vision care devices and equipment market are Essilor, Johnson & Johnson, ZEISS, The Cooper Companies, Novartis, Bausch & Lomb, Nidek Co. Ltd., Valeant Pharmaceuticals, Luxottica GROUP, and Escalon. North America was the largest region in global vision care devices and equipment market in 2022. Asia-Pacific was the second-largest region in the vision care devices and equipment market. The regions covered in global vision care devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the vision care devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The vision care devices and equipment market consist of sales of equipment such as vitrector, Phoropter, VT 1 vision screener, contact lenses and spectacles and others that are used for proper diagnosis and treating vision of an eye. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global vision care devices and equipment market is segmented - 1) By Type: Intraocular Lens, Ophthalmic Lasers, Glaucoma Drainage Devices, Contact Lenses, Other Types 2) By Aplication: Vision Care, Diagnosis, Surgery 3) By End User: Hospitals, Ambulatory Surgery Centers, Optical Centers, Other End users

Dry eye medication refers to the drugs or medication that is used to treat dry eye by increasing your eye moisture. A multifactorial condition of the tears and ocular surface known as dry eye causes symptoms such as pain, blurred vision, and tear film instability, as well as the possibility of ocular surface injury. The main types of dry eye medication are aqueous dry eye syndrome and evaporative dry eye syndrome. Dry eye syndrome is a frequent problem that arises when the tears aren't able to keep the eyes lubricated enough. Tears may be insufficient and unstable for a variety of causes. The different types of products include liquid drops, gel, liquid wipes, and eye ointment and are used by hospital pharmacies, eye health clinics, retail pharmacies, and online pharmacies. The dry eye medication market research report is one of a series of new reports from The Business Research Company that provides dry eye medication market statistics, including dry eye medication industry global market size, regional shares, competitors with a dry eye medication market share, detailed dry eye medication market segments, market trends and opportunities, and any further data you may need to thrive in the dry eye medication industry. This dry eye medication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global dry eye medication market size will grow from $8.67 billion in 2022 to $9.62 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dry eye medication market size is expected to grow to $13.99 billion in 2027 at a CAGR of 9.8%. The increased number of cases of dry eye disease results in an increased demand for its treatment. Factors such as aging, lack of vitamin A, wearing lenses, eye surgeries, direct contact with dry wind or smoke, and exposing one’s eyes to screens for a long duration increase the occurrence of the dry eye more likely. For example, a survey conducted by the American Academy of Ophthalmology reported that in the USA, nearly 3.2 million women and 1.68 million men, over the age of 50 were affected by dry eye syndrome. Similarly, a study conducted by the Indian Journal of Ophthalmology indicated a 32% prevalence of dry eye disease in the Northern part of India. the rising prevalence of the disease would increase the demand for its treatment and ultimately facilitate the growth of this market. The market for dry eye medication is restricted by the long approval process that is undertaken before any drug is approved by the concerned authority. The standard protocol for testing any new drug demands a series of tests and trials including laboratory tests, animal model tests, and clinical trials. Most drugs fail during clinical trials and only a small percent of them successfully move forward. The cumbersome process of obtaining approvals takes a longer duration of time and restricts the growth of this market. For example, in 2020, Eysuvis, a drug that addresses the short-term treatment needs of patients living with dry eye disease, was approved by the Food and Drug Administration (FDA) after its safety and effectiveness were assessed on more than 2900 patients with the disease in different clinical trials. Similarly, Kissei Pharmaceutical announced to discontinue the development of the KCT-0809 drug after it failed to pass the 3rd phase of clinical trials. Treatment for dry eye disease improved with the incorporation of modern techniques that helped invent advanced hyaluronic acid-based lubricants and lipid emulsions. This technology replaces artificial tears that include isotonic sodium chloride and provides long-lasting lubrication on the surface of the eye. For instance, Allergan, a global pharmaceutical company, launched Refresh Repair Lubricant Eye Drops which are designed to repair and protect the eyes from dry eye disease and improve the clarity of vision and are formulated with carboxymethylcellulose (CMC), hyaluronic acid, and osmoprotectants. These components maintain the health of the ocular surface and safeguard epithelial cells. Advances in technology will have a positive effect on the market. The dry eye medication market is strictly regulated by government agencies such as USFDA (Food and Drug Administration), the European Medicines Agency (EMA), and others. For instance, in the USA, FDA evaluates and approves the drugs meant for dry eye treatment. According to Section 201(g) of the FDA and CFR (Code of federal regulations) act, the licenses are granted to drug manufacturing companies allowing them to sell only those drugs that are safe and clinically effective. FDA demands several tests and several clinical trial rounds before granting such approvals. For example, FDA approved Kala Pharmaceuticals’ eye-related drug called INVELTYS. In July 2022, Alcon, a Switzerland-based ophthalmology company acquired Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals for a deal amount of $60 million. Through this acquisition, Alcon acquires Inveltys treatment of post-operative inflammation and pain following ocular surgery and expands its portfolio. Kala Pharmaceuticals is a US-based pharmacuetical company operating in drug eye medication. Major players in the dry eye medication market are Novartis, Allergan, Otsuka, Santen Pharmaceutical, Auven Therapeutics, Akorn, Valent Pharmaceuticals, Johnson and Johnson Vision, Alcon and Bausch & Lomb. North America was the largest region in the dry eye medication market in 2022. Middle East is expected to be the fastest-growing region in the global dry eye medication market during the forecast period. The regions covered in the global dry eye medication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dry eye medication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dry eye medication market consists of sales of polyethylene glycol, polyvinyl alcohol, propylene glycol, carboxymethylcellulose, povidone, glycerine, and mineral oil. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global dry eye medication market is segmented - 1) By Type: Aqueous dry eye syndrome, Evaporative dry eye syndrome 2) By end-user: Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies 3) By Product Type: Liquid Drops, Gel, Liquid Wipes, Eye Ointment

The ophthalmology drugs market consists of sales of ophthalmology drugs and related services by entities (organizations, sole traders and partnerships) that produce ophthalmology drugs to treat eye related diseases. The ophthalmology drugs industry includes establishments that produce pharmaceutical drugs to treat glaucoma diseases, anti- inflammatory and tear stimulating drugs under dry eye medications drugs, and other drugs for treating retinal disorders and allergies. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax. The main types of ophthalmology drugs are antiglaucoma drugs, dry eye medication, and other ophthalmological drugs (retinal disorders, anti-infectives/allergy). Anti-glaucoma drugs are medications used to prevent or treat glaucoma, which is a disease in which the optic nerve is damaged, resulting in progressive, irreversible vision loss. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global ophthalmology drugs market size is expected to grow from $50.62 billion in 2021 to $56.07 billion in 2022 at a compound annual growth rate (CAGR) of 10.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The ophthalmology drugs market is expected to reach $127.15 billion in 2026 at a CAGR of 22.7%. The expected rise in eye laser surgeries will contribute to the ophthalmology drugs market. Ophthalmology research has proved a link between laser eye surgeries and the prevalence of dry eye disorders. In an eye laser procedure, cutting of some nerves in the cornea leads to reduction in corneal sensitivity, in response to which, eyes may not sense the need for lubrication, causing the body to produce fewer tears. Dry eye is a common side effect after laser vision correction surgeries. It is estimated that almost half of the patients that undergo a laser surgery experience some degree of dry eye condition following the procedure. The number of eye laser procedures rose to 720,000 a year in 2020. A rising number of people going for laser eye surgeries is expected to increase the demand for dry eye medications in the forecast period driving the ophthalmology drugs market. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the ophthalmology drugs market. Drug manufacturers are increasingly developing ophthalmic drugs with anti-inflammatory agents to ease patient treatment for dry eye syndrome. Anti-inflammatory drugs are widely used for the treatment of the inflammation produced by the dry eye syndrome, with the topical corticosteroid drops being the most common therapy. Corticosteroids can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye. However, prolonged usage of corticosteroids has seen to produce side effects that include risk of bacterial or fungal infection, elevated intraocular pressure and cataract formation. As a consequence, NSAIDs are increasingly being used as dry eye treatment instead of steroids to minimize the side effects. For instance, Aciex Therapeutics, a US-based pharmaceutical company, is developing NSAIDs which decrease ocular discomfort. Major companies in the ophthalmology drugs market include Regeneron Pharmaceuticals, Inc., Novartis AG, AbbVie, Santen Pharmaceutical Co., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc., Bayer AG, Sumitomo Chemical Co ltd, Mitsubishi Tanabe Pharma Corporation and Horizon Therapeutics plc. North America was the largest region in the ophthalmology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the ophthalmology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ophthalmology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global ophthalmology drugs market is segmented - 1) By Type: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs